3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
14
Pancreatic Neoplasms
9
Colonic Neoplasms
5
Rectal Neoplasms
4
Ovarian Neoplasms
3
Gastrointestinal Stromal Tumors
3
Biliary Tract Neoplasms
3
Triple Negative Breast Neoplasms
2
Melanoma
2
Uveal Melanoma
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Thyroid Neoplasms
1
Stomach Neoplasms
1
Spinocerebellar Degenerations
1
Prostatic Neoplasms
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Neurofibromatosis 1
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Lymphoma
1
Lung Neoplasms
1
Klatskin Tumor
1
Hereditary Sensory and Autonomic Neuropathies
1
Hematologic Neoplasms
1
Glioma
1
Gallbladder Neoplasms
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Interventions
pembrolizumab
4
Nivolumab
3
sintilimab
2
Oxaliplatin
2
Leucovorin
2
Fluorouracil
2
Bevacizumab
2
vicriviroc
1
trifluridine tipiracil drug combination
1
spartalizumab
1
relatlimab
1
regorafenib
1
epacadostat
1
dabrafenib
1
copanlisib
1
binimetinib
1
atezolizumab
1
Tiragolumab
1
Irinotecan
1
Immune Checkpoint Inhibitors
1
Fulvestrant
1
E7046
1
Cetuximab
1
Capecitabine
1
Azacitidine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Spinocerebellar Degenerations
×
binimetinib
×
Gastrointestinal
×
Clear all
NCT03374254
2024-11-21
KEYNOTE-651
Merck Sharp & Dohme LLC
Phase 1
Completed
116 enrolled
18 charts